NASDAQ:NEXI NexImmune (NEXI) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free NEXI Stock Alerts $2.73 -0.27 (-9.00%) (As of 06/10/2024 ET) Add Compare Share Share Today's Range$2.73▼$2.9950-Day Range$2.73▼$5.3652-Week Range$1.25▼$28.69Volume11,642 shsAverage Volume1.25 million shsMarket Capitalization$3.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get NexImmune alerts: Email Address Ad Traders AgencyHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About NexImmune Stock (NASDAQ:NEXI)NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Read More NEXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEXI Stock News HeadlinesJune 4, 2024 | americanbankingnews.comNexImmune (NASDAQ:NEXI) Shares Up 1.3%May 26, 2024 | nasdaq.comNexImmune, Inc. Common Stock (NEXI) After-HoursMay 20, 2024 | msn.comNEXI Stock Earnings: NexImmune Reported Results for Q1 2024April 17, 2024 | investorplace.comNEXI Stock Earnings: NexImmune Reported Results for Q4 2023April 16, 2024 | theglobeandmail.comAcute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsightApril 15, 2024 | msn.comPortage mulls company closure, pauses enrolment for lead clinical programmeApril 2, 2024 | msn.comXilio fires 21% of its workforce and reprioritises pipelineFebruary 7, 2024 | msn.comNexImmune Announces New Offerings in Recent Press ReleaseFebruary 6, 2024 | markets.businessinsider.comNexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 6, 2024 | msn.comNexImmune Secures Funding Through Equity and Warrant SalesFebruary 3, 2024 | msn.comNexImmune Ends Stock Sale Agreement, Raises $5.1 MillionFebruary 2, 2024 | msn.comNexImmune slips after securities offeringFebruary 2, 2024 | finance.yahoo.comNexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 13, 2024 | nasdaq.comNexImmune, Inc. Common Stock (NEXI)January 9, 2024 | investorplace.comNexImmune (NEXI) Stock Rockets 80% Ahead of Potential LiquidationDecember 26, 2023 | bizjournals.comNexImmune's future in limbo as Gaithersburg biotech extends liquidation voteDecember 10, 2023 | ca.finance.yahoo.comNexImmune, Inc. (NEXI) Stock Price, News, Quote & History - Yahoo FinanceDecember 1, 2023 | investorplace.comNEXI Stock Halted: What’s Going on With NexImmune Shares Today?December 1, 2023 | investorplace.comWhy Is NexImmune (NEXI) Stock Up 353% Today?November 23, 2023 | morningstar.comNexImmune Inc Ordinary Shares NEXINovember 8, 2023 | bizjournals.comGaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employeesNovember 6, 2023 | msn.comWhat's Going On With Neximmune (NEXI) Stock Monday?November 3, 2023 | msn.comWhy Neximmune (NEXI) Stock Is Getting HammeredNovember 3, 2023 | marketwatch.comNexImmune Shares Slide Premarket as Biotech Says It Will LiquidateOctober 24, 2023 | finance.yahoo.comNexImmune, Yale, and JDRF Extend Research Partnership for Type 1 DiabetesSee More Headlines Receive NEXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today6/10/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NEXI CUSIPN/A CIK1538210 Webwww.neximmune.com Phone301-825-9810FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($24.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-324.33% Return on Assets-183.73% Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio1.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book0.82Miscellaneous Outstanding Shares1,370,000Free Float1,105,000Market Cap$3.74 million OptionableNot Optionable Beta1.95 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Kristi Jones R.Ph. (Age 61)CEO, President & Director Comp: $989.28kDr. Mathias Oelke Ph.D. (Age 56)Chief Scientific Officer Comp: $605.78kMr. John Trainer M.B.A. (Age 50)Consultant Comp: $1.33MMr. Albert Nicholas Marchio II (Age 72)Interim CFO & Principal Accounting Officer Mr. Karen HaslbeckHead of Human ResourcesDr. Daniel P. BednarikSenior Vice President of Molecular Engineering & Protein DesignDr. Robert Douglas Knight M.D. (Age 73)Chief Medical Officer Comp: $454.77kMr. Chad RubinSenior Vice President of Corporate AffairsDr. Jack A. Ragheb M.D.Ph.D., Senior Vice President of Translational ScienceMr. Matthew SchillerHead of Business DevelopmentMore ExecutivesKey CompetitorsGalera TherapeuticsNASDAQ:GRTXKaleido BiosciencesNASDAQ:KLDOSensei BiotherapeuticsNASDAQ:SNSEOrgenesisNASDAQ:ORGSAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 303,399 shares on 3/22/2024Ownership: 1.192%Alan S RoemerSold 3,833 sharesTotal: $8,279.28 ($2.16/share)View All Insider TransactionsView All Institutional Transactions NEXI Stock Analysis - Frequently Asked Questions How have NEXI shares performed in 2024? NexImmune's stock was trading at $2.22 at the beginning of the year. Since then, NEXI stock has increased by 23.0% and is now trading at $2.73. View the best growth stocks for 2024 here. Are investors shorting NexImmune? NexImmune saw a increase in short interest in May. As of May 15th, there was short interest totaling 11,700 shares, an increase of 88.7% from the April 30th total of 6,200 shares. Based on an average trading volume of 50,300 shares, the short-interest ratio is presently 0.2 days. Currently, 1.0% of the shares of the company are short sold. View NexImmune's Short Interest. When is NexImmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our NEXI earnings forecast. How were NexImmune's earnings last quarter? NexImmune, Inc. (NASDAQ:NEXI) announced its quarterly earnings results on Tuesday, April, 16th. The company reported ($4.99) EPS for the quarter. When did NexImmune's stock split? NexImmune's stock reverse split on the morning of Thursday, October 19th 2023. The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did NexImmune IPO? NexImmune (NEXI) raised $75 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. acted as the underwriters for the IPO. How do I buy shares of NexImmune? Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NEXI) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.